시장보고서
상품코드
1267372

세계의 감염증 체외진단 시장 : 규모, 점유율, 동향 분석, 기회 및 예측(2019-2029년) : 제품별, 기술별, 용도별, 검사 장소별, 지역별

Infectious Disease In Vitro Diagnostics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Technology ; By Application ; By Test Location ; By Region

발행일: | 리서치사: Blueweave Consulting | 페이지 정보: 영문 400 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 감염증 체외진단 시장 규모는 2022년 354억 1,000만 달러에 달했습니다. 향후 2023년부터 2029년까지 연평균 -1.38%의 CAGR로 소폭 감소하여 2029년에는 329억 8,000만 달러에 달할 것으로 예상됩니다.

본 보고서는 세계 감염증 체외진단 시장에 대해 조사했으며, 시장 개요와 함께 제품별/기술별/용도별/검사장소별/지역별 동향, 경쟁 상황, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 조사 프레임워크

제2장 주요 요약

제3장 세계의 감염증 체외진단 시장 인사이트

  • 업계 밸류체인 분석
  • DROC 분석
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
  • 기술 진보/최근 개발
  • 규제 프레임워크
  • Porter's Five Forces 분석

제4장 세계의 감염증 체외진단 시장 개요

  • 시장 규모와 예측, 2019년-2029년
  • 시장 점유율과 예측
    • 제품별
      • 장비
      • 시약
      • 소프트웨어
    • 기술별
      • 면역분석법
      • 분자진단 학
      • 미생물학
      • 기타
    • 용도별
      • MRSA
      • 연쇄구균
      • 클로스트리듐·디피실
      • VRE
      • CRE
      • 기타
    • 검사장소 별
      • POC(Point of Care)
      • 중앙연구소
      • 기타
    • 지역별
      • 북미
      • 유럽
      • 아시아태평양
      • 라틴아메리카
      • 중동 및 아프리카

제5장 북미 감염증 체외진단 시장

제6장 유럽 감염증 체외진단 시장

제7장 아시아태평양 감염증 체외진단 시장

제8장 라틴아메리카 감염증 체외진단 시장

제9장 중동 및 아프리카 감염증 체외진단 시장

제10장 경쟁 구도

제11장 COVID-19가 세계의 감염증 체외진단 시장에 미치는 영향

제12장 기업 개요

  • QIAGEN
  • BD
  • bioMerieux SA
  • F. Hoffmann-La Roche, Ltd.
  • Hologic, Inc.(Gen-Probe)
  • Abbott
  • Quidel Corp.
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • OraSure Technologies, Inc.
  • 기타

제13장 주요 전략적 추천 사항

제14장 조사 방법

LSH 23.05.12

Global Infectious Disease In Vitro Diagnostics Market Size to Reach USD 33 Billion by 2029.

Global infectious disease in vitro diagnostics market is flourishing because of growing geriatric population susceptible to infectious diseases and surging demand for POC testing owing to the pandemic.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global infectious disease in vitro diagnostics market size at USD 35.41 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave anticipates global infectious disease in vitro diagnostics market size to slightly decline at a CAGR of -1.38% reaching a value of USD 32.98 billion by 2029. Major growth drivers for global infectious disease in vitro diagnostics market include increasing number of elderly individuals who are vulnerable to contagious illnesses, the COVID-19 pandemic's high requirement for point-of-care (PoC) testing, greater recognition of the importance of early detection, and the growing occurrence of infectious diseases. The pandemic led to a significant shift in the market, as innovative products for testing SARS-CoV-2 were launched, resulting in substantial growth in the industry in 2020 and 2021. The increasing adoption of these products played a crucial role in the growth of the market. As a result of the rapid installation of PCR instruments, there has been an opportunity to utilize PCR tests for other infectious diseases, such as influenza, due to the declining need for SARS-CoV-2 tests in 2022. The growing geriatric population is expected to be one of the growth drivers of this market, given that aging is the leading risk factor for the development of diseases such as cardiovascular and neurological diseases. However, high cost associated with testing is anticipated to hinder the growth of global infectious disease in vitro diagnostics market during the period in analysis.

Global Infectious Disease In Vitro Diagnostics Market - Overview:

The infectious disease in vitro diagnostics (IVD) market refers to the use of diagnostic tests and devices to detect and diagnose infectious diseases in biological samples such as blood, urine, and other bodily fluids. These tests are performed in vitro, meaning outside of the body in a laboratory setting. The IVD market for infectious diseases includes a range of tests such as immunoassays, molecular diagnostics, and microbiology culture tests, among others. These tests aid in the identification of infectious agents such as bacteria, viruses, fungi, and parasites, and help in the management and treatment of infectious diseases.

Impact of COVID-19 on Global Infectious Disease In Vitro Diagnostics Market

COVID-19 had a positive impact on the infectious disease in vitro diagnostics market. The increased need for detecting cases during the pandemic resulted in higher utilization rates of IVD devices. Regulatory authorities also made testing mandatory to contain the spread of the disease, further driving up demand for IVD devices. However, with the decrease in COVID-19 cases, there may be a decrease in demand for diagnostics. Nonetheless, the infectious disease in vitro diagnostics market is expected to continue growing due to the emergence of new diseases. More people are becoming health-conscious and monitoring their health regularly, which is also contributing to the rise in demand for IVD devices.

Global Infectious Disease In Vitro Diagnostics Market - By Application:

Based on application, global infectious disease in vitro diagnostics market is segmented into MRSA, Streptococcus, Clostridium Difficile, VRE, CRE, and others (Respiratory Virus, Candida, TB And Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, and COVID-19). The COVID-19 application segment was the most dominant segment in the global industry. This can be attributed to the increased utilization of SARS-CoV-2 testing to curb the spread of the virus. Additionally, government initiatives to improve public testing and the launch of innovative products have been significant factors driving the growth of this sector. The TB and HIV segments have also experienced rapid growth due to improved testing methods. Furthermore, the respiratory virus segment's influenza testing has accelerated with the introduction of new diagnostic tests that allow differentiation between SARS-CoV-2 and influenza, facilitating prompt treatment. Tuberculosis, caused by Mycobacterium tuberculosis, is a contagious infection that remains a global epidemic. The WHO reported 130 new cases per 100,000 annually in 2020, but there has been a decline in the incidence rate in recent years, with a 9% drop between 2015 and 2019.

Competitive Landscape:

Major players operating in global infectious disease in vitro diagnostics market include: QIAGEN, BD, bioMerieux SA, F. Hoffmann-La Roche, Ltd., Hologic, Inc. (Gen-Probe), Abbott, Quidel Corp., Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Danaher Corp., and OraSure Technologies, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Infectious Disease In Vitro Diagnostics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Infectious Disease In Vitro Diagnostics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Infectious Disease In Vitro Diagnostics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing Geriatric Population Susceptible to Infectious Diseases
      • 3.2.1.2. High Demand for POC Testing Owing to the Pandemic
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost Associated with Testing
    • 3.2.3. Opportunities
      • 3.2.3.1. Rising Prevalence of Infectious Diseases.
    • 3.2.4. Challenges
      • 3.2.4.1. Lack of Accurate result of Testing
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Infectious Disease In Vitro Diagnostics Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Instruments
      • 4.2.1.2. Reagents
      • 4.2.1.3. Software
    • 4.2.2. By Technology
      • 4.2.2.1. Immunoassay
      • 4.2.2.2. Molecular Diagnostics
      • 4.2.2.3. Microbiology
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. MRSA
      • 4.2.3.2. Streptococcus
      • 4.2.3.3. Clostridium Difficile
      • 4.2.3.4. VRE
      • 4.2.3.5. CRE
      • 4.2.3.6. Others (Respiratory Virus, Candida, TB And Drug-resistant TB, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HPV, HIV, Hepatitis C, Hepatitis B, COVID-19)
    • 4.2.4. By Test Location
      • 4.2.4.1. Point of Care
      • 4.2.4.2. Central Laboratories
      • 4.2.4.3. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Infectious Disease In vitro Diagnostics Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Technology
    • 5.2.3. By Application
    • 5.2.4. By Test Location
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Product
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Application
      • 5.2.5.1.4. By Test Location
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Product
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Application
      • 5.2.5.2.4. By Test Location

6. Europe Infectious Disease In vitro Diagnostics Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Test Location
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Product
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Application
      • 6.2.5.1.4. By Test Location
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Product
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Application
      • 6.2.5.2.4. By Test Location
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Product
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Application
      • 6.2.5.3.4. By Test Location
      • 6.2.5.4. France
      • 6.2.5.4.1. By Product
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Application
      • 6.2.5.4.4. By Test Location
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Product
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Application
      • 6.2.5.5.4. By Test Location
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Product
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Application
      • 6.2.5.6.4. By Test Location
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Product
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Application
      • 6.2.5.7.4. By Test Location
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Product
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Application
      • 6.2.5.8.4. By Test Location
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Product
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Application
      • 6.2.5.9.4. By Test Location

7. Asia-Pacific Infectious Disease In vitro Diagnostics Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Test Location
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Product
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Application
      • 7.2.5.1.4. By Test Location
      • 7.2.5.2. India
      • 7.2.5.2.1. By Product
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Application
      • 7.2.5.2.4. By Test Location
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Product
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Application
      • 7.2.5.3.4. By Test Location
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Product
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Application
      • 7.2.5.4.4. By Test Location
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Product
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Application
      • 7.2.5.5.4. By Test Location
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Product
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Application
      • 7.2.5.6.4. By Test Location
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Product
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Application
      • 7.2.5.7.4. By Test Location
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Product
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Application
      • 7.2.5.8.4. By Test Location
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Product
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Application
      • 7.2.5.9.4. By Test Location
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Product
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Application
      • 7.2.5.10.4. By Test Location

8. Latin America Infectious Disease In vitro Diagnostics Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Test Location
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Product
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Application
      • 8.2.5.1.4. By Test Location
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Product
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Application
      • 8.2.5.2.4. By Test Location
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Product
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Application
      • 8.2.5.3.4. By Test Location
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Product
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Application
      • 8.2.5.4.4. By Test Location
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Product
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Application
      • 8.2.5.5.4. By Test Location

9. Middle East & Africa Infectious Disease In vitro Diagnostics Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Test Location
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Product
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Application
      • 9.2.5.1.4. By Test Location
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Product
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Application
      • 9.2.5.2.4. By Test Location
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Product
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Application
      • 9.2.5.3.4. By Test Location
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Product
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Application
      • 9.2.5.4.4. By Test Location
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Product
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Application
      • 9.2.5.5.4. By Test Location
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Product
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Application
      • 9.2.5.6.4. By Test Location
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Product
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Application
      • 9.2.5.7.4. By Test Location
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Product
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Application
      • 9.2.5.8.4. By Test Location

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Infectious Disease In Vitro Diagnostics Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Infectious Disease In Vitro Diagnostics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. QIAGEN
  • 12.2. BD
  • 12.3. bioMerieux SA
  • 12.4. F. Hoffmann-La Roche, Ltd.
  • 12.5. Hologic, Inc. (Gen-Probe)
  • 12.6. Abbott
  • 12.7. Quidel Corp.
  • 12.8. Siemens Healthineers AG
  • 12.9. Bio-Rad Laboratories, Inc.
  • 12.10. Danaher Corp.
  • 12.11. OraSure Technologies, Inc.
  • 12.12. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제